Effect of Bredinine Combined with Middle Dose Glucocorticoid in the Treatment of IgA Nephropathy

doi:10.12114/j.issn.1007-9572.2019.00.806

Abstract

Abstract: Background　IgA nephropathy is the most common primary glomerular disease in China，which has a serious impact on the health and quality of life of patients.Glucocorticoid and bredinine are commonly used in the treatment of IgA nephropathy，but there are a few studies on the combination of them.Objective　To study the clinical effect of bredinine combined with middle dose glucocorticoid in the treatment of IgA nephropathy in order to provide basis for clinical treatment.Methods　From April 2015 to April 2017，45 patients with IgA nephropathy in Wuhan Fourth Hospital were selected as the study objects.The patients were randomly divided into three groups：bredinine group，middle dose glucocorticoid group and bredinine combined with middle dose glucocorticoid group，with 15 cases in each group.The patients in bredinine group were treated with bredinine tablets，150 mg/time，once a day.The patients in the middle dose glucocorticoid group were treated with prednisone acetate tablets，40 mg•kg-1•d-1.On the basis of the treatment with prednisone acetate tablets，bredenine tablets were added to the bredenine combined with middle close glucocorticoid group.The dosage and usage were the same as that of bredenine group.The treatment time of the three groups was 6 months.The total efficiency of the three groups was recorded.The levels of serum creatinine，urinary microalbumin，urea nitrogen，24 h urinary protein，IgA and TGF-β1 before and after treatment were measured.And the adverse reactions were calculated.Results　The total effective rate of bredinine combined with middle dose glucocorticoid group was higher than that of bredinine group and middle dose glucocorticoid group（P<0.05）.The level of serum creatinine，urea nitrogen and 24 h urine protein in bredinine combined with middle dose glucocorticoid group were lower than those in bredinine group and middle dose glucocorticoid group，and the level of microalbumin in urine was higher than that in bredinine group and middle dose glucocorticoid group（P<0.05）.The levels of serum creatinine and 24 h urinary protein in three groups were lower than those before treatment，and the levels of urinary microalbumin were higher than those before treatment（P<0.05）.The urea nitrogen level of bredinine group，bredinine combined with middle dose glucocorticoid group after treatment was lower than that before treatment，and that of middle dose glucocorticoid group after treatment was higher than that before treatment（P<0.05）.The levels of IgA and TGF-β1 in bredinine group and middle dose glucocorticoid group were lower than those in bredinine group and middle dose glucocorticoid group（P<0.05）.The levels of IgA and TGF-β1 in three groups were lower than those before treatment（P<0.05）.There was no significant difference in the incidence of adverse reactions among the three groups（P>0.05）.Conclusion　Bredinine combined with glucocorticoid has a significant effect in the treatment of IgA nephropathy.It can improve the renal function，reduce the level of IgA and TGF-β1，and has a high safety.It provides a new treatment idea for IgA nephropathy.

Key words: Glomerulonephritis, IGA；IgA nephropathy；Bredinine；Glucocorticoid；Treatment outcome

摘要： 背景　IgA肾病是目前我国最常见的原发性肾小球疾病，对患者的身体健康以及生活质量造成严重的影响。糖皮质激素、布累迪宁是临床较为常用的治疗IgA肾病的药物，但关于二者联合应用的研究还相对较少。目的　研究布累迪宁联合中等剂量糖皮质激素治疗IgA肾病的临床疗效，以期为临床治疗提供依据。方法　选取2015年4月—2017年4月武汉市第四医院IgA肾病患者45例为研究对象。采用随机数字表法将患者分为布累迪宁组、中等剂量糖皮质激素组和布累迪宁联合中等剂量糖皮质激素组，各15例。布累迪宁组患者使用布累迪宁片进行治疗，150 mg/次，1次/d。中等剂量糖皮质激素组患者使用口服醋酸泼尼松片进行治疗，40 mg•kg-1•d-1。布累迪宁联合中等剂量糖皮质激素组在口服醋酸泼尼松片治疗的基础上加用布累迪宁片，剂量及用法和布累迪宁组相同。三组患者的治疗时间均为6个月。记录三组总有效率，检测三组治疗前及治疗后血清肌酐、尿微量白蛋白、尿素氮水平和24 h尿蛋白定量及IgA、转化生长因子（TGF）-β1水平，统计不良反应情况。结果　布累迪宁联合中等剂量糖皮质激素组总有效率高于布累迪宁组、中等剂量糖皮质激素组（P<0.05）。布累迪宁联合中等剂量糖皮质激素组治疗后血清肌酐、尿素氮水平及24 h尿蛋白定量低于布累迪宁组、中等剂量糖皮质激素组，尿微量白蛋白水平高于布累迪宁组、中等剂量糖皮质激素组（P<0.05）。三组治疗后血清肌酐水平、24 h尿蛋白定量低于本组治疗前，尿微量白蛋白水平高于本组治疗前（P<0.05）；布累迪宁组、布累迪宁联合中等剂量糖皮质激素组治疗后尿素氮水平低于本组治疗前，中等剂量糖皮质激素组治疗后尿素氮水平高于本组治疗前（P<0.05）。布累迪宁联合中等剂量糖皮质激素组治疗后IgA、TGF-β1水平低于布累迪宁组、中等剂量糖皮质激素组（P<0.05）。三组治疗后IgA、TGF-β1水平低于本组治疗前（P<0.05）。三组不良反应发生率比较，差异无统计学意义（P>0.05）。结论　布累迪宁联合中等剂量糖皮质激素治疗IgA肾病的效果显著，能够改善患者肾功能，降低IgA、TGF-β1水平，安全性较高，为IgA肾病的治疗提供了新的治疗思路。

关键词: 肾小球肾炎, IGA；IgA肾病；布累迪宁；糖皮质激素；治疗结果

熊艳,许传文,黄杰等. 布累迪宁联合中等剂量糖皮质激素治疗IgA肾病的效果研究[J]. 中国全科医学, 2020, 23(6): 667-671. DOI: 10.12114/j.issn.1007-9572.2019.00.806.

References

［1］林婉清，张月华，王辉.醋酸泼尼松联合来氟米特治疗IgA肾病的临床观察及护理措施［J］．中国生化药物杂志，2017，37（9）：295-296.
LIN W Q，ZHANG Y H，WANG H.Clinical observation and nursing intervention of prednisone acetate combined with leflunomide in the treatment of IgA nephropathy［J］．Chinese Journal of Biochemical Pharmaceutics，2017，37（9）：295-296.
［2］李利利，王阿妮，庄稼，等．不同性别原发性IgA肾病患者临床病理特征的对比分析［J］．西安交通大学学报：医学版，2017，38（2）：247-250，260．DOI：10.7652/jdyxb201702018.
LI L L，WANG A N，ZHUANG J，et al．Clinical and pathological features of primary IgA nephropathy in patients of different gender［J］．Journal of Xi'an Jiaotong University：Medical Sciences，2017，38（2）：247-250，260．DOI：10.7652/jdyxb201702018.
［3］沈琪，欧阳小琳，杨彤，等．糖皮质激素与非免疫抑制剂治疗原发性IgA肾病的Meta分析［J］．中国全科医学，2014，17（11）：1288-1292，1296．DOI：10.3969/j.issn.1007-9572.2014.11.19.
SHEN Q，OUYANG X L，YANG T，et al．Meta-analysis of glucocorticoids and non-immunosuppressor in ImmunoglobulinA nephropathy［J］．Chinese General Practice，2014，17（11）：1288-1292，1296．DOI：10.3969/j.issn.1007-9572.2014.11.19.
［4］王树忠，高武.泼尼松联合咪唑立宾对高蛋白尿IgA肾病患者肾功能的影响［J］．中国药业，2018，27（16）：30-33．DOI：10.3969/j.issn.1006-4931.2018.16.010.
WANG S Z，GAO W.Effect of prednisone combined with mizoribine on renal function in patients with high proteinuria type of IgA nephropathy［J］．China Pharmaceuticals，2018，27（16）：30-33．DOI：10.3969/j.issn.1006-4931.2018.16.010.
［5］张宏.KDIGO指南解读：IgA肾病治疗［J］．中国实用内科杂志，2012，32（12）：925-927.
ZHANG H.IgA nephropathy：interpretation of KDIGO guideline［J］．Chinese Journal of Practical Internal Medicine，2012，32（12）：925-927.
［6］ROBERTS I S.Pathology of IgA nephropathy［J］．Nat Rev Nephrol，2014，10（8）：445-454．DOI：10.1038/nrneph.2014.92.
［7］BERTHOUX F C，MOHEY H，AFIANI A.Natural history of primary IgA nephropathy［J］．Semin Nephrol，2008，28（1）：4-9．DOI：10.1016/j.semnephrol.2007.10.001.
［8］汤跃武，吴泽成.激素联合不同免疫抑制剂治疗原发性IgA肾病的疗效及安全性［J］．实用医学杂志，2016，32（10）：1687-1689．DOI：10.3969/j.issn.1006-5725.2016.10.041.
［9］何川鄂，朱平，杨芦蓉，等．临床表现为肾病综合征的IgA肾病临床分析及治疗效果［J］．广东医学，2014，35（16）：2586-2589．DOI：10.3969/j.issn.1001-9448.2014.16.042.
［10］张红，孙嫱.咪唑立宾在IgA肾病治疗中的研究进展［J］．中国医师杂志，2015（z1）：244-246，247．DOI：10.3760/j.issn.1008-1372.2015.z1.119.
［11］BERTHOUX F C，MOHEY H，AFIANI A.Natural history of primary IgA nephropathy［J］．Semin Nephrol，2008，28（1）：4-9．DOI：10.1016/j.semnephrol.2007.10.001.
［12］TANG S C W，TANG A W C，WONG S S H，et al．Long-term study of mycophenolate mofetil treatment in IgA nephropathy［J］．Kidney International，2010，77（6）：543-549．DOI：10.1038/ki.2009.499.
［13］WANG D H，WANG F，DING J，et al．Retrospective study of primary IgA nephropathy with crescent formation and/or rapidly progressive glomerulonephritis in children［J］．Chinese Journal of Pediatrics，2015，53（9）：670-675.
［14］吴文英，张如峰，马凤英，等．别嘌呤醇治疗痛风性肾病疗效观察及血肌酐、尿素氮水平的影响［J］．中国生化药物杂志，2017，37（9）：170-171，174.
WU W Y，ZHANG R F，MA F Y，et al．Effect of allopurinol on the treatment of gouty nephropathy and the effects of serum creatinine and urea nitrogen levels［J］．Chinese Journal of Biochemical Pharmaceutics，2017，37（9）：170-171，174.
［15］龚国琴，张莉萍.当归拈痛丸治疗痛风性肾病疗效及对血肌酐、尿素氮水平影响［J］．中国生化药物杂志，2017，37（9）：62-64.
GONG G Q，ZHANG L P.Clinical effects and influence on serum creatinine and blood urea nitrogen of Danggui Niantong pill in treatment of gouty nephropathy［J］．Chinese Journal of Biochemical Pharmaceutics，2017，37（9）：62-64.
［16］李娅，王伟铭，任红，等．沷尼松联合环磷酰胺治疗免疫球蛋白A肾病伴肾病综合征和肾功能不全［J］．上海医学，2012，35（9）：746-750.
LI Y，WANG W M，REN H，et al．Prednisone plus cyclophosphamide therapy for IgA nephropathy patients with impaired renal function and nephrotic syndrome［J］．Shanghai Medical Journal，2012，35（9）：746-750.
［17］乔平，曾和松，黄芬，等．尿微量白蛋白/肾小球滤过率与对比剂肾病发生的相关性［J］．实用医学杂志，2015，31（11）：1790-1793．DOI：10.3969/j.issn.1006-5725.2015.11.020.
QIAO P，ZENG H S，HUANG F，et al．Relationship between microalbuminuria to estimated glomerular filtration rate ratio and incidence of contrast induced nephropathy［J］．The Journal of Practical Medicine，2015，31（11）：1790-1793．DOI：10.3969/j.issn.1006-5725.2015.11.020.
［18］祝爽爽，李永强，周树录，等．血清中IgA/C3比值在IgA肾病诊断预测中的价值及其与IgA肾病临床及病理联系［J］．南方医科大学学报，2015，35（12）：1683-1688．DOI：10.3969/j.issn.1673-4254.2015.12.04.
ZHU S S，LI Y Q，ZHOU S L，et al．Value of serum IgA/C3 ratio in the diagnosis of IgA nephropathy and its correlation with the clinicopathological features［J］．Journal of Southern Medical University，2015，35（12）：1683-1688．DOI：10.3969/j.issn.1673-4254.2015.12.04.
［19］李海剑，程根阳，刘慧，等．IgA肾病肾组织中OPN、TGF-β1的表达及其与临床、病理的关系［J］．中国现代医学杂志，2017，27（9）：59-63．DOI：10.3969/j.issn.1005-8982.2017.09.012.
LI H J，CHENG G Y，LIU H，et al．Expressions of OPN and TGF-β1 in renal tissue of patients with IgA nephropathy and their correlations with clinical and pathological parameters［J］．China Journal of Modern Medicine，2017，27（9）：59-63．DOI：10.3969/j.issn.1005-8982.2017.09.012.
［20］杨青梅，鲍晓荣.原发性IgA肾病外周血IL-17及TGF-β1的表达及意义［J］．中国临床医学，2013，20（2）：154-156．DOI：10.3969/j.issn.1008-6358.2013.02.017.

[1]	ZHOU Wenjing, SHANG Shili, YANG Qian, FENG Yuerong, LI Jun. Correlation of Platelet-albumin Ratio with Clinicopathological Features of IgA Nephropathy [J]. Chinese General Practice, 2023, 26(29): 3657-3664.
[2]	SUN Shuaigang, SHENG Xiaoxiao, ZHANG Wenhui, TIAN Huijuan, ZHAI Yaling. The Analysis of Clinicopathological Characters and Short-term Prognosis in Idiopathic Membranous Nephropathy Patients with Immunoglobulin G4 Combined with Other Different Immunoglobulin G Subtypes Deposition [J]. Chinese General Practice, 2023, 26(21): 2632-2638.
[3]	YAN Peng, SONG Jianling, FANG Xiangdong. Recent Developments in Parathyroid Hormone Type 1 Receptor and Kidney Disease [J]. Chinese General Practice, 2023, 26(11): 1398-1403.
[4]	Nephrology Branch of China Association of Chinese Medicine, Nephrology Committee of Guangdong Provincial Association of Chinese Medicine, YANG Lihong, SU Peiling, BAO Kun. Clinical Practice Guideline for Chinese Medicine in the Treatment of Idiopathic Membranous Nephropathy (2021) [J]. Chinese General Practice, 2023, 26(06): 647-659.
[5]	Jianghua KE, Shuwei DUAN, Linchang LIU, Shuang LI, Yujing KE, Yilun QU, Jin YAO, Xiangmei CHEN. Clinical, Pathological and TCM Syndromes of Primary IgA Nephropathy with Malignant Hypertension [J]. Chinese General Practice, 2022, 25(27): 3395-3403.
[6]	LIU Tongtong，WANG Yuyang，YANG Liping，MAO Huimin，ZHAN Yongli. Efficacy and Safety of Different Pharmacological Interventions for Progressive IgA Nephropathy：a Network Meta-analysis　 [J]. Chinese General Practice, 2021, 24(8): 989-1000.
[7]	YU Baisong，LIU Bing. Advances in the Treatment of Primary IgA Nephropathy [J]. Chinese General Practice, 2021, 24(23): 2985-2991.
[8]	ZHANG Dongliang，LUO Li，ZHENG Liren，HU Nana，WAN Li，YANG Qinghua，ZHANG Zhoucang. Rituximab Salvage Therapy Is Inappropriate for Secondary Refractory Nephropathy　 [J]. Chinese General Practice, 2020, 23(36): 4645-4650.
[9]	ZHAI Yaling，LONG Xiaoqing，GAO Jingge，LU Shan，ZHAO Zhanzheng. Functional Difference Exploration of Circulating Immune Complex between Patients with IgA Nephropathy Only and Both with Diabetes Mellitus　 [J]. Chinese General Practice, 2020, 23(17): 2115-2119.
[10]	ZHAI Yaling，GAO Jingge，LONG Xiaoqing，LI Ruman，DOU Yanna，LIU Dong，XIAO Jing，ZHAO Zhanzheng，LIU Zhangsuo，CHENG Genyang. Clinical Significance of Serum a Proliferation-inducing Ligand in Patients with Idiopathic Membranous Nephropathy　 [J]. Chinese General Practice, 2020, 23(14): 1764-1768.
[11]	LIANG Yan，ZHANG Xiaoling，LIU Bing，ZHU Qing，SHAO Fengmin. Curative Effect of Tripterygium Glycosides Combined with Irbesartan on IgA Nephropathy with Increased Urinary Podocyte Excretion　 [J]. Chinese General Practice, 2019, 22(12): 1426-1431.
[12]	LI Zhijuan，BAO Ying，HUANG Huimei，TANG Jun，ZHANG Min. Analysis of Clinical Characteristics and Prognosis of Children with Glomerulonephritis after Acute Streptococcal Infection with Nephrotic Proteinuria [J]. Chinese General Practice, 2018, 21(33): 4134-4137.
[13]	CHENG Gen-yang1，2*，WANG Yun1，YUAN Wen-ming1，ZHANG Li-jie1，XIAO Jing1，2，ZHAO Zhan-zheng1，2. Clinicopathological Features and Prognosis in Patients with Proliferative and Sclerosing IgA Nephropathy with Anemia　 [J]. Chinese General Practice, 2018, 21(18): 2185-2189.
[14]	LU Huan，TANG Shui-fu，CHEN Gang-yi，SU Bao-lin，ZHAN Dong-xiang，WU Xing-bo，WANG Chao，LUO Yue-zhong*. Mechanism of Aqueous Extract from Wenyanglishui Decoction in Protecting Mouse Podocytes from Injury Caused by Serum from IMN Patients with Syndrome of Spleen and Kidney Yang Deficiency　#br# [J]. Chinese General Practice, 2018, 21(15): 1862-1868.